Nivalis Therapeutics, Inc. (NVLS) Makes Smashing Debut

Nivalis Therapeutics Inc (NASDAQ:NVLS) is among several drugmakers soaring this afternoon

Jun 17, 2015 at 2:40 PM

FIT
NVLS

Nivalis Therapeutics Inc (NASDAQ:NVLS) began trading publicly today, and so far, the results have been great. While the IPO hasn't been as highly publicized as Fitbit Inc's (NYSE:FIT) upcoming debut, shares of the drugmaker are up an impressive 8.7% at $15.22

For those unfamiliar, NVLS is a pharmaceutical firm focused on treating patients with cystic fibrosis. The company's leading candidate is N91115, which is designed to stabilize defective cystic fibrosis transmembrane conductane regulator (CFTR) activity.

While Nivalis Therapeutics Inc's (NASDAQ:NVLS) session has been successful, a number of drugmakers have surged even more sharply today. In fact, my colleague Josh Selway earlier highlighted a pair of biotechs flirting with fresh highs.

Follow @Schaeffers

$40 Gets You 4 High-Conviction Trades. Let's Go.

We just booked back-to-back double-digit gains on Celsius and Palantir in Trade of the Week, and we’re eyeing even bigger wins!

Every week starts with a fully defined options trade straight from the desk Schaeffer’s Senior V.P. of Research, Todd Salamone, backed by 30+ years of proven market experience and disciplined risk management.

Right now, you can get 4 total trades over the next 4 weeks for $40 – just $10 per trade.

👉 Sign Up Now to Receive Your First Trade!